Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00198-015-3123-0.

Title:
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review | Osteoporosis International
Description:
Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,643,328 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, google, scholar, cas, bone, diabetes, type, central, metab, endocrinol, risk, effects, patients, fracture, rosiglitazone, dois, metformin, clin, mellitus, mineral, density, thiazolidinediones, fractures, pioglitazone, receptor, res, study, int, randomized, effect, women, doijc, differentiation, cells, article, cell, rats, diabetic, treatment, antidiabetic, miner, trial, resorption, osteoporosis, metabolism, glucagonlike, peptide, eur, postmenopausal, marrow,

Topics {✒️}

gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinol pi3-kinases/akt signalling pathway peroxisome proliferator-activated receptors oral anti-diabetic drugs ppar-gamma regulates osteoclastogenesis pi3-kinase/akt pathway streptozocin-induced diabetic rats nord-trøndelag health survey advanced glycation end-products dipeptidyl peptidase-iv inhibitor month download article/chapter sodium-glucose cotransport inhibition estrogen-deprived rats treated tak1/tab1/nik cascade dipeptidyl peptidase-iv inhibition reverse hyperlipidic-related osteopenia obese candy-fed rats controlled case-series study camp-linked glp-1 receptor anti-diabetic drug metformin anti-diabetic drugs long-term glycaemic control promoting osteoblast/osteocyte apoptosis university campus bio-medico increases bone turnover population-based study idf diabetes atlas metformin prevents anti-osteogenic international osteoporosis foundation osteoblastic mc3t3-e1 cells peptide-1 receptor agonist open-label trial today clinical trial case–control study nuclear factor kappa ppar-gamma function oral hypoglycemic agents body fat mass glucose-lowering drugs bone marrow fat mesenchymal stem cells alpha agonist fenofibrate privacy choices/manage cookies oral antidiabetic medication de laet cedh trabecular bone microarchitecture ppargamma agonist brl49653 rosiglitazone induces decreases human bone marrow van der klift

Questions {❓}

  • Bazelier MT, Vestergaard P, Gallagher AM et al (2012) Risk of fracture with thiazolidinediones: disease or drugs?
  • Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous?
  • Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
         description:Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health.
         datePublished:2015-04-25T00:00:00Z
         dateModified:2015-04-25T00:00:00Z
         pageStart:2073
         pageEnd:2089
         sameAs:https://doi.org/10.1007/s00198-015-3123-0
         keywords:
            BMD
            Bone turnover markers
            Diabetes
            Fracture
            Oral anti-diabetic drugs
            Osteoporosis
            Orthopedics
            Endocrinology
            Rheumatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-015-3123-0/MediaObjects/198_2015_3123_Fig1_HTML.gif
         isPartOf:
            name:Osteoporosis International
            issn:
               1433-2965
               0937-941X
            volumeNumber:26
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer London
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. Palermo
               affiliation:
                     name:University Campus Bio-Medico of Rome
                     address:
                        name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L. D’Onofrio
               affiliation:
                     name:University Campus Bio-Medico of Rome
                     address:
                        name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Eastell
               affiliation:
                     name:University of Sheffield
                     address:
                        name:Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. V. Schwartz
               affiliation:
                     name:University of California San Francisco
                     address:
                        name:Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. Pozzilli
               affiliation:
                     name:University Campus Bio-Medico of Rome
                     address:
                        name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of London
                     address:
                        name:Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Napoli
               affiliation:
                     name:University Campus Bio-Medico of Rome
                     address:
                        name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                        type:PostalAddress
                     type:Organization
                     name:Washington University in St. Louis
                     address:
                        name:Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
      description:Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health.
      datePublished:2015-04-25T00:00:00Z
      dateModified:2015-04-25T00:00:00Z
      pageStart:2073
      pageEnd:2089
      sameAs:https://doi.org/10.1007/s00198-015-3123-0
      keywords:
         BMD
         Bone turnover markers
         Diabetes
         Fracture
         Oral anti-diabetic drugs
         Osteoporosis
         Orthopedics
         Endocrinology
         Rheumatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-015-3123-0/MediaObjects/198_2015_3123_Fig1_HTML.gif
      isPartOf:
         name:Osteoporosis International
         issn:
            1433-2965
            0937-941X
         volumeNumber:26
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer London
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. Palermo
            affiliation:
                  name:University Campus Bio-Medico of Rome
                  address:
                     name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L. D’Onofrio
            affiliation:
                  name:University Campus Bio-Medico of Rome
                  address:
                     name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Eastell
            affiliation:
                  name:University of Sheffield
                  address:
                     name:Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. V. Schwartz
            affiliation:
                  name:University of California San Francisco
                  address:
                     name:Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. Pozzilli
            affiliation:
                  name:University Campus Bio-Medico of Rome
                  address:
                     name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of London
                  address:
                     name:Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Napoli
            affiliation:
                  name:University Campus Bio-Medico of Rome
                  address:
                     name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
                     type:PostalAddress
                  type:Organization
                  name:Washington University in St. Louis
                  address:
                     name:Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Osteoporosis International
      issn:
         1433-2965
         0937-941X
      volumeNumber:26
Organization:
      name:Springer London
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Campus Bio-Medico of Rome
      address:
         name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
         type:PostalAddress
      name:University Campus Bio-Medico of Rome
      address:
         name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
         type:PostalAddress
      name:University of Sheffield
      address:
         name:Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
         type:PostalAddress
      name:University of California San Francisco
      address:
         name:Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
         type:PostalAddress
      name:University Campus Bio-Medico of Rome
      address:
         name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
         type:PostalAddress
      name:University of London
      address:
         name:Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
         type:PostalAddress
      name:University Campus Bio-Medico of Rome
      address:
         name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
         type:PostalAddress
      name:Washington University in St. Louis
      address:
         name:Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. Palermo
      affiliation:
            name:University Campus Bio-Medico of Rome
            address:
               name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
               type:PostalAddress
            type:Organization
      name:L. D’Onofrio
      affiliation:
            name:University Campus Bio-Medico of Rome
            address:
               name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
               type:PostalAddress
            type:Organization
      name:R. Eastell
      affiliation:
            name:University of Sheffield
            address:
               name:Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
               type:PostalAddress
            type:Organization
      name:A. V. Schwartz
      affiliation:
            name:University of California San Francisco
            address:
               name:Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:P. Pozzilli
      affiliation:
            name:University Campus Bio-Medico of Rome
            address:
               name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
               type:PostalAddress
            type:Organization
            name:University of London
            address:
               name:Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
               type:PostalAddress
            type:Organization
      name:N. Napoli
      affiliation:
            name:University Campus Bio-Medico of Rome
            address:
               name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
               type:PostalAddress
            type:Organization
            name:Washington University in St. Louis
            address:
               name:Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
      name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
      name:Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
      name:Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
      name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
      name:Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
      name:Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
      name:Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(519)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • AOS
  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.78s.